Phospho-HER3 (Tyr1276)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 13092R
英文名称Phospho-HER3 (Tyr1276)
中文名称磷酸化HER3抗体
别 名Her3/ErbB3(phospho-Tyr1276); p-HRE3 (Tyr1276); ErbB 3 (phospho Y1276); ERBB3; c erbB 3; c erbB3; ERBB3 protein; erbB3 S; Glial growth factor receptor; HER 3; HER3; LCCS2; MDA BF 1; MGC88033; p180 ErbB3; p45 sErbB3; p85 sErbB3; proto-oncogene-like protein c ErbB 3; proto-oncogene-like protein c ErbB3; receptor tyrosine protein kinase ERB3; Receptor tyrosine protein kinase erbB 3; Receptor tyrosine protein kinase erbB3; Tyrosine kinase type cell surface receptor HER3; ERBB3_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 细胞膜受体 G蛋白偶联受体 肿瘤细胞生物标志物 G蛋白信号
抗体来源Rabbit
克隆类型Polyclonal
Phospho-HER3 (Tyr1276)抗体交叉反应 Human, Rat, Dog, Pig, Cow, Horse,
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量148kDa
细胞定位细胞膜 分泌型蛋白
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human HER3 around the phosphorylation site of Tyr1276:GD(p-Y)AA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-HER3 (Tyr1276)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
ErbB3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ErbB3 is a membrane-bound protein which has a neuregulin binding domain but not an active kinase domain. It can therefore bind this ligand but cannot convey a signal into the cell via protein phosphorylation. However it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers including prostate, bladder and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. Isoform 2 lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported but they have not been thoroughly characterized. Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2); also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord.
Function:
Binds and is activated by neuregulins and NTAK.
Subunit:
Monomer and homodimer. Heterodimer with each of the other ERBB receptors (Potential). Interacts with CSPG5, PA2G4, GRB7 and MUC1.
Subcellular Location:
Isoform 1: Cell membrane; Single-pass type I. membrane protein. Isoform 2: Secreted.
Tissue Specificity:
Epithelial tissues and brain.
Post-translational modifications:
Ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. Subject to autophosphorylation.
DISEASE:
Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.
Similarity:
Belongs to the protein kinase superfamily.
Tyr protein kinase family.
EGF receptor subfamily.
Contains 1 protein kinase domain.
SWISS:
P21860
Gene ID:
2065
Phospho-HER3 (Tyr1276)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-HER3 (Tyr1276)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 Anillin 胞环蛋白肌动蛋白结合蛋白抗体
合格 合格 SIP1 Smad蛋白相互作用蛋白1抗体
合格 合格 SIP1 Smad蛋白相互作用蛋白1抗体
合格 Nogo R 轴索过度生长抑制因子受体/Nogo受体抗体
合格 PODXL 足细胞特异蛋白抗体
合格 PODXL 足细胞特异蛋白抗体
合格 合格 BRCA1 乳腺癌易感基因1抗体
合格 Caspase 4 半胱胺酸蛋白酶蛋白-4抗体
合格 合格 Tubulin, Alpha 4a 微管蛋白α/Tubulin α抗体
合格 TUBA1A + TUBA1B 微管蛋白α 1A/1B
合格 Leptin receptor 瘦素受体抗体
合格 Leptin receptor 瘦素受体抗体
合格 PFKL 6磷酸果糖激酶（肝型）抗体
合格 FOS B FosB蛋白抗体
合格 CUG-BP1 胞苷尿苷鸟苷结合蛋白1抗体
合格 Transferrin 转铁蛋白/血清铁传递蛋白抗体
合格 ZNF143 锌指蛋白143抗体
合格 KAT9 组蛋白乙酰转移酶KAT9抗体
合格 OLIG3 少突胶质细胞转录因子3抗体
合格 LRCH1 富含亮氨酸重复家庭蛋白1抗体
合格 合格 AKR1C2 胆汁酸结合蛋白DDH2抗体
合格 合格 CYP2C19 细胞色素P450 2C19抗体
合格 HDAC9 组蛋白去乙酰化酶9抗体
合格 NCOA2/KAT13C 类固醇受体激活蛋白2抗体
合格 SOX10 转录因子SOX10抗体
合格 AKT2 蛋白激酶B2抗体
合格 SOX7 转录因子SOX7抗体
合格 合格 Syntaxin-1B
合格 合格 Phospho-FAK (Tyr925) 磷酸化粘着斑激酶抗体
合格 CACNB1 钙通道电压依赖性β1蛋白抗体
合格 Glycophorin A 血型糖蛋白A/涎糖蛋白抗体